AIM ImmunoTech (AIM)
0.44
+0.04 (10.00%)
Upcoming Events
Latest Headlines
Form 8-K AIM ImmunoTech Inc. For: Jun 09
June 10, 2026 4:59 PM - SEC Filing
Form 424B5 AIM ImmunoTech Inc.
June 10, 2026 2:01 PM - SEC Filing
AIM ImmunoTech raises $2.65 million in registered direct offering
June 9, 2026 9:30 AM - StreetInsider
AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rules
June 9, 2026 9:30 AM - Globe NewsWire
AIM ImmunoTech (AIM) Halted, News Pending
June 9, 2026 9:27 AM - StreetInsider
AIM ImmunoTech (AIM) files for 31.3M share offering by selling stockholders
June 8, 2026 4:08 PM - StreetInsider
Form S-1 AIM ImmunoTech Inc.
June 8, 2026 4:06 PM - SEC Filing
AIM ImmunoTech reports progress in pancreatic cancer drug trial
June 8, 2026 8:34 AM - StreetInsider
Form 8-K AIM ImmunoTech Inc. For: Jun 04
June 4, 2026 9:01 AM - SEC Filing
Ravi Chandran Krishnadas joins RWS as Senior Vice President & Country Lead, India
June 1, 2026 4:00 AM - PR NewsWire
Form SCHEDULE 13G AIM ImmunoTech Inc. Filed by: INTRACOASTAL CAPITAL, LLC
May 27, 2026 5:15 PM - SEC Filing
Form 8-K AIM ImmunoTech Inc. For: May 20
May 21, 2026 11:31 AM - SEC Filing
Form 424B5 AIM ImmunoTech Inc.
May 21, 2026 11:30 AM - SEC Filing
AIM ImmunoTech raises $2.4 million through stock and warrant offering
May 20, 2026 3:02 PM - StreetInsider
AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement
May 20, 2026 3:02 PM - Globe NewsWire
AIM ImmunoTech (AIM) halted, news pending
May 20, 2026 2:58 PM - StreetInsider
Form 424B5 AIM ImmunoTech Inc.
May 19, 2026 5:20 PM - SEC Filing
AIM ImmunoTech extends debt maturity to 2027, reports equity increase
May 19, 2026 8:06 AM - StreetInsider
Form 8-K AIM ImmunoTech Inc. For: May 18
May 19, 2026 8:03 AM - SEC Filing
AIM ImmunoTech Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to June 2027, Enhancing Financial Flexibility and Supporting Strategic Clinical Prior
May 19, 2026 8:02 AM - Globe NewsWire
Form 10-Q AIM ImmunoTech Inc. For: Mar 31
May 15, 2026 4:10 PM - SEC Filing
Form 8-K AIM ImmunoTech Inc. For: May 14
May 14, 2026 8:46 AM - SEC Filing
AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer
May 14, 2026 8:41 AM - Globe NewsWire
Form SCHEDULE 13G AIM ImmunoTech Inc. Filed by: Orca Capital AG
May 12, 2026 4:31 PM - SEC Filing
Form 8-K AIM ImmunoTech Inc. For: May 08
May 12, 2026 4:28 PM - SEC Filing
Form 8-K AIM ImmunoTech Inc. For: May 07
May 8, 2026 8:50 AM - SEC Filing
AIM ImmunoTech raises $4.2 million through warrant exercise
May 8, 2026 8:41 AM - StreetInsider
AIM ImmunoTech, Inc. Announces Exercise of Warrants for Approx. $4.2 Million in Gross Proceeds
May 8, 2026 8:40 AM - Globe NewsWire
AIM ImmunoTech reports 50% response rate in ovarian cancer trial
May 7, 2026 8:23 AM - StreetInsider
AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential
May 7, 2026 8:23 AM - Globe NewsWire
AIM ImmunoTech plans phase 3 pancreatic cancer trial for Ampligen
April 16, 2026 11:45 AM - StreetInsider
AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP
April 16, 2026 11:45 AM - Globe NewsWire
Form 8-K AIM ImmunoTech Inc. For: Apr 10
April 10, 2026 4:33 PM - SEC Filing
Form 424B5 AIM ImmunoTech Inc.
April 10, 2026 4:31 PM - SEC Filing
AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event
April 9, 2026 8:01 AM - Globe NewsWire
Form 10-K AIM ImmunoTech Inc. For: Dec 31
March 27, 2026 5:31 PM - SEC Filing
Form 4 AIM ImmunoTech Inc. For: Mar 16 Filed by: Equels Thomas K
March 16, 2026 5:31 PM - SEC Filing
Form 4 AIM ImmunoTech Inc. For: Mar 16 Filed by: CHEMEROW DAVID I.
March 16, 2026 5:30 PM - SEC Filing
Full Article List
